Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors

1 Mar 2009

Abstract excerpt

PURPOSE OF REVIEW: Small molecule inhibitors targeting the CCR5 coreceptor represent a new class of drugs for treating HIV-1 infection. Maraviroc has received regulatory approvals, and vicriviroc is in phase 3 trials. Understanding how resistance to these drugs develops and is diagnosed is essential to guide clinical practice. We review what has been learned from in-vitro resistance studies, and how this relates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemokine receptors and signaling
Share to HIV Research and Treatment
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19339950
DOI: 10.1097/coh.0b013e3283223d46

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitorsPMID 19339950Read ↗

HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.Semantic proximity Read ↗

Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes.Semantic proximity Read ↗

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 CoreceptorSemantic proximity Read ↗

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.Semantic proximity Read ↗

Resistance to novel drug classesSemantic proximity Read ↗

Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.Semantic proximity Read ↗

Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.Semantic proximity Read ↗

HIV-1 Entry, Inhibitors, and ResistanceSemantic proximity Read ↗

A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacitySemantic proximity Read ↗

V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and VicrivirocSemantic proximity Read ↗

A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.Semantic proximity Read ↗

Resistance to the CCR5 Inhibitor 5P12-RANTES Requires a Difficult Evolution from CCR5 to CXCR4 Coreceptor UseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.